

ASX ANNOUNCEMENT

24 August 2022

APPENDIX 4D AND HALF YEARLY FINANCIAL REPORT

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) releases its Appendix 4D – Half Yearly (HY22) Financial Report and commentary for the period ended 30 June 2022.

HIGHLIGHTS

- First-in-human DurAVR™ THV six-month follow-up demonstrating excellent results with an 86% improvement in haemodynamics
- Completion of first-in-human study with eight more patients successfully treated
- Expansion of Medical Advisory Board with the appointments of Australian interventional cardiologists Dr Karl Poon and Associate Professor Dion Stub
- Research Partnership with Yale University and the Yale Cardiovascular Research Group further investigating haemodynamic function post transcatheter aortic valve replacement in patients
- Strategic intellectual property strengthening with additional patents filed to increase DurAVR™ heart valve manufacturing capacity and to enhance the ADAPT® sterilisation process and shelf life
- \$US20 million (\$A27.6 million) placement of 1,840,000 new shares to Perceptive Life Sciences Master Fund at \$A15 per share

FINANCIAL SUMMARY

- Revenues from ordinary activities for the half year ended 30 June 2022 were \$2.5M (HY21: \$3.2M) largely generated from manufacturing of the CardioCel™ and VascuCel™ patches under the LeMaitre Vascular Inc. agreement.
- Net loss after tax was \$22.1M (2021: \$10.4M), primarily due to the significant expansion of the research and development program including the preparation and completion of the second cohort in its DurAVR™ first-in-human patient study and recruitment of additional personnel predominately engaged in R&D as we prepare for the Early Feasibility Study in the United States.
- The closing cash position at 30 June 2022 was \$33.1M (2021: \$21.3M) with net working capital of \$29.9M (2021: \$12.9M). This uplift was primarily attributable to the Perceptive placement of 1,840,000 new shares raising \$US20M (\$A27.6M). With a 14% holding, Perceptive is Anteris' largest shareholder.

Anteris CEO Wayne Paterson said “We are delighted with the outcomes of the first-in-human trials which validate our view that Anteris’ DurAVR™ prosthetic valve has superior haemodynamics. The DurAVR™ will revolutionise outcomes, particularly in young patients.

The value of the market for DurAVR™ THV system is estimated to be worth \$US10b by 2025 and Anteris’ DurAVR™ prosthetic valve combined with the Company’s ADAPT® tissue platform will offer a compelling choice for surgeons and patients.”

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and additional information

This announcement was authorised by the Board of Directors.

For more information:

Deanne Curry

GRACosway

E: investors@anteristech.com

M: +61 414 388 997

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech